Davidson Kempner Capital Management’s Orchestra BioMed OBIO Stock Holding History

Davidson Kempner Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-245,213	Closed	-$2.45M	–	403
2022 Q4	$2.45M	Hold	245,213	–	–	0.05%	247
2022 Q3	$2.43M	Sell	245,213 -230,000	-48%	-$2.28M	0.04%	290
2022 Q2	$4.73M	Sell	475,213 -500,000	-51%	-$4.97M	0.08%	213
2022 Q1	$9.66M	Hold	975,213	–	–	0.12%	133
2021 Q4	$9.75M	Hold	975,213	–	–	0.14%	117
2021 Q3	$9.6M	Buy	975,213 +50,000	+5%	+$494K	0.14%	126
2021 Q2	$9.44M	Buy	925,213 +300,487	+48%	+$3.11M	0.07%	160
2021 Q1	$6.96M	Buy	624,726 +196,871	+46%	+$2.4M	0.07%	172
2020 Q4	$5.39M	Sell	427,855 -25,000	-6%	-$285K	0.06%	175
2020 Q3	$4.98M	Buy	+452,855	New	+$5.09M	0.07%	171

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SFG

SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Davidson Kempner Capital Management's OBIO Position: Q1 2023 in Review

Davidson Kempner Capital Management sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 245,213 shares — an estimated $2.45M sold.

Davidson Kempner Capital Management first reported a position in OBIO in Q3 2020 and held it in 10 quarters. The position peaked at $9.75M in Q4 2021. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

Davidson Kempner Capital Management reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
Davidson Kempner Capital Management sold 245,213 Orchestra BioMed shares in Q1 2023, an estimated $2.45M.
Davidson Kempner Capital Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 10 quarters.
Davidson Kempner Capital Management's Orchestra BioMed position peaked at $9.75M in Q4 2021.
22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2023, filed 15 May 2023.